1.. Introduction {#S0001}
================

Sarcoidosis is a multisystem granulomatous disease of unknown etiology that can present with nonspecific features, often resulting in delayed diagnosis \[[1](#CIT0001)\]. The diagnosis requires the presence of non-caseating granulomas on biopsy. While sarcoidosis occurs worldwide and affects all ages and races, the incidence and prevalence in the USA is rare in Hispanics (4.3 and 21.7 per 100,000, respectively) as compared to African-Americans (17.8 and 141.4 per 100,000, respectively) and Caucasians (8.1 and 49.8 per 100,000, respectively) \[[2](#CIT0002)\].

We report herein the unique presentation of sarcoidosis in a Hispanic gentleman with no prior medical problems.

2.. Case {#S0002}
========

A 55-year-old Hispanic male presented to the hospital at the request of his primary care provider due to a two-month history of joint pain in the shoulders, elbows, wrists, and knees, decreased appetite and 20-pound weight loss in the setting of hypercalcemia, anemia, elevated serum creatinine, and positive urine Bence-Jones protein. He also endorsed a severely pruritic rash, chills, and fatigue that began three weeks prior to admission, but denied fever, headache, alopecia, chest pain, cough, diaphoresis, dyspnea, abdominal pain, nausea, vomiting, or diarrhea. Travel history was significant for a trip to Mexico 3 months prior to admission. His occupation is in landscaping.

Physical exam was significant for diffuse joint tenderness without swelling or warmth, and multiple raised, blanchable, erythematous papules and plaques distributed on the back, arms, legs, and face, as well as leonine facies ([Figures 1](#F0001) and [2](#F0002)). Labs were significant for a serum white blood cell count (WBC) of 3,700/microL (normal 4,500--1100/microL), absolute lymphocytes 400/microL (1,000--4,000/microL), hemoglobin of 8.6 g/dL (normal 14.0--17.5 g/dL), corrected calcium of 14.4 mg/dL (normal 8.6--10.3 mg/dL), 1,25-dihydroxyvitamin D of 154 pg/mL (normal 18--72 pg/mL), 25-hydroxyvitamin D of 20 ng/mL (normal 30--100 ng/mL), PTH of 1 pg/mL (normal 14--64 pg/mL), PTH-related protein of 24 pg/mL (normal 14--27 pg/mL), creatinine of 3.23 mg/dL (unknown baseline, normal 1.13 and 0.93 mg/dL), and 24-h urine protein of 700 mg (normal \< 100 mg).10.1080/20009666.2019.1607503-F0001Figure 1.Left arm, antecubital area, discrete, multiple well-demarcated, edematous, erythematous papules and plaques.10.1080/20009666.2019.1607503-F0002Figure 2.Face, frontal view. Leonine facies: Diffuse skin infiltration, multiple nodular lesions.

Due to positive Bence-Jones protein on urinalysis from an outside laboratory, the diagnosis of gammopathy was entertained. However, an in-house evaluation for monoclonal gammopathy, including serum and urine protein electrophoresis and immunofixation, skeletal survey, and bone marrow biopsy, was negative for gammopathy as well as infection and malignancy. Interestingly, skin punch biopsy revealed non-caseating granulomatous dermatitis, with negative stains for atypical mycobacteria, tuberculosis and fungal organisms ([Figure 3](#F0003)). CT chest showed non-specific calcified granulomas at the hilum and left lung without hilar adenopathy or infiltrates. Renal biopsy demonstrated mild arterial nephrocalcinosis and segmental thickening of the glomerular basement membrane. Tissue cultures, serum Quantiferon TB gold, coccidioides antibodies, histoplasma antibodies, and blastomyces antibodies were all negative. Serum Angiotensin Converting Enzyme (ACE) level was normal. Screening electrocardiogram and transthoracic echocardiogram did not demonstrate any evidence of cardiac involvement. By exclusion of alternative diagnoses, the patient was treated for sarcoidosis with prednisone 20 mg daily, yielding substantial improvements in the rash, and arthralgia. The hypercalcemia resolved with steroids, fluid resuscitation, calcitonin, and pamidronate which also led to the improvement of renal function ([Figure 4](#F0004)). Two weeks after discharge, he was started on azathioprine 50 mg daily with subsequent prednisone taper. As an outpatient, the patient was doing well with resolution of his rash, and azathioprine was up-titrated to 100 mg daily. The patient was subsequently lost to follow-up.10.1080/20009666.2019.1607503-F0003Figure 3.Histopathology, skin biopsy, taken from left arm. H&E staining 200 x magnification showing non-caseating granulomatous dermatitis.10.1080/20009666.2019.1607503-F0004Figure 4.Trends in WBC, serum creatinine, and albumin-corrected calcium over 10 hospital days. There is sustained improvement in WBC, creatinine, and calcium levels after administration of oral prednisone, as noted on hospital day 6.

3.. Discussion {#S0003}
==============

Sarcoidosis is relatively rare in Hispanics, with a reported prevalence of 21.7 per 100,000, when compared to other ethnic groups \[[2](#CIT0002)\]. Skin involvement occurs in 25% to 35% of patients with sarcoidosis, and can present at any stage of illness \[[3](#CIT0003)\]. While sarcoidosis is typically asymptomatic and rarely associated with pruritus and pain, this patient presented with a pruritic rash and leonine faces, reported only in a few cases worldwide \[[4](#CIT0004),[5](#CIT0005)\]. The skin biopsy clutched the diagnosis of a granulomatous disease, which may be related to tubercular (though granulomas would be caseating), fungal, parasitic, or viral infections, malignancy or autoimmune diseases like sarcoidosis, granulomatosis with polyangiitis, Crohn's disease, or even common variable immune deficiency (CVID). However, a comprehensive evaluation for these alternative diagnoses was deemed negative despite recent travel and an occupation that exposes him to infectious risk. Testing for plasma cell dyscrasias, protein electrophoresis, light chain testing, and bone marrow biopsy were all unrevealing. Serologies, blood cultures, and pathology staining were negative for infectious etiologies described above.

The patient lacked symptoms suggestive of inflammatory bowel disease, and abdominal CT imaging was unremarkable. The diagnosis of sarcoidosis was ultimately made after excluding other etiologies and noting concomitant laboratory findings of hypercalcemia, hypervitaminosis D, skin biopsy with noncaseating granulomas, skin rash, joint pain, and constitutional symptoms \[[6](#CIT0006)\].

An additional unique point to this case is that the majority (70%) of patients with cutaneous involvement also demonstrates pulmonary symptoms \[[7](#CIT0007)\], but our patient lacked pulmonary complaints and demonstrated only two calcified granulomas on advanced pulmonary imaging.

Reports implicate the presence of hypercalcemia in 10 to 20% of patients with sarcoidosis \[[8](#CIT0008)\]. The enzyme, 1-α hydroxylase, converts 25-hydroxyvitamin D to 1,25-dihydroxyvitamin D, the active form of the vitamin, which may result in hypercalcemia, hypercalciuria, and nephrolithiasis. Longstanding hypercalcemia and hypercalciuria can cause nephrocalcinosis and renal failure \[[9](#CIT0009),[10](#CIT0010)\], as seen in our case. The patient had a suppressed PTH level suggesting that hypercalcemia was not parathyroid hormone dependent. Successful treatment of the hypercalcemia with steroids and other therapies often improves, but usually does not completely resolve the renal dysfunction, as also seen in our patient.

Sarcoidosis may be associated with a reduction in any blood cell line. The most common hematologic problem is lymphopenia, which is a reflection of the sequestration of lymphocytes into the areas of inflammation \[[11](#CIT0011)\]. Anemia, in this case, could be multifactorial, including anemia of inflammation, renal insufficiency, and lack of nutrients (decreased appetite, weight loss).

The majority of sarcoidosis-related manifestations resolve within 2--5 years. Certain risk factors at presentation may be associated with worse prognosis, such as fibrosis on chest imaging, presence of lupus pernio, bone cysts, nephrolithiasis, and cardiac disease \[[11](#CIT0011)\].

While a large number of patients with sarcoidosis, typically pulmonary sarcoidosis, never needs medications, symptomatic sarcoidosis is treated with corticosteroids as the first line of treatment \[[12](#CIT0012)\]. The decision to add steroid-sparing agents is dependent on the tolerability, duration, and dosage of corticosteroids. Specifically, if one is unable to safely taper off steroid treatment without a recurrence of sarcoidosis symptoms, steroid-sparing therapy is indicated. Such treatments may include hydroxychloroquine, methotrexate, azathioprine, mycophenolate, leflunomide \[[13](#CIT0013)\], cyclophosphamide, infliximab \[[14](#CIT0014),[15](#CIT0015)\], adalimumab, and newer agents like rituximab \[[16](#CIT0016)\]. In the 1950s, corticotropin (Acthar gel, subcutaneous) demonstrated efficacy in treating pulmonary sarcoidosis and was approved by the FDA to do so on the basis of case reports \[[17](#CIT0017)\]. Shortly thereafter, hydrocortisone and prednisone were FDA approved for the treatment of symptomatic sarcoidosis, proving to be more cost-effective and convenient than Acthar injections \[[18](#CIT0018)\]. Our patient demonstrated a good response to a low-dose steroid therapy by improving skin lesions, arthralgia, leukopenia, hypercalcemia, and serum creatinine; however, his prognosis may not be favorable due to concern for a component of his renal dysfunction related to hypercalcemia.
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